Information Provided By:
Fly News Breaks for March 27, 2018
ANAB, DBVT
Mar 27, 2018 | 07:21 EDT
Deutsche Bank analyst Andrew Peters says his bullish thesis on DBV Technologies (DBVT) remains intact following last night's peanut allergy data from AnaptysBio (ANAB). While the early Phase 2a data suggest AnaptysBio's ANB020 could have an effect both on sensitivity to peanut protein as well as symptom severity during the food challenge, the data are "far from clear" and potential timelines to market suggest minimal impact on DBV's Viaskin Peanut, Peters tells investors in a research note. The analyst views the ANB020 data as not directly competitive to Viaskin Peanut given that they are in adults. Further, Peters notes that his Viaskin Peanut model already incorporates "conservative assumptions" around overall market penetration and share. The analyst reiterated a Buy rating on DBV Technologies with a $33 price target.
News For DBVT;ANAB From the Last 2 Days
There are no results for your query DBVT;ANAB